PHARMACEUTICAL 2023

XOMA Royalty Corp
Rank 46 of 471



TOP RATED 2023

RealRate

PHARMACEUTICAL 2023

XOMA Royalty Corp
Rank 46 of 471

XOMA

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 142% points.The greatest weakness of XOMA Royalty Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 6.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 384%, being 140% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	61,253
Cost of Goods Sold	0
Intangible Assets	15,150
Liabilities, Current	6,818
Liabilities, Non-Current	0
Other Assets	63,972
Other Compr. Net Income	0
Other Expenses	82
Other Liabilities	9,550
Other Net Income	295
Other Revenues	6,027
Property and Equipment	7.0
Research and Development	153
Selling, General and Administrative Expense	23,191

Output Variable	Value in 1000 USD
Assets	140,382
Liabilities	16,368
Expenses	23,426
Revenues	6,027
Stockholders Equity	124,014
Net Income	-17,104
Comprehensive Net Income	-17,104
BaseVar	93,249
ECR before LimitedLiability	323%
Economic Capital Ratio	384%